David T Teachey Selected Research

David T Teachey Research Topics

Disease

41	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 07/2005
23	Neoplasms (Cancer) 01/2022 - 06/2009
21	Cytokine Release Syndrome 01/2022 - 04/2013
14	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2022 - 12/2016
13	Leukemia 01/2022 - 10/2012
10	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 08/2007
8	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 10/2012
8	Cytopenia 09/2016 - 12/2009
7	Autoimmune Lymphoproliferative Syndrome 01/2020 - 09/2006
6	Macrophage Activation Syndrome 12/2021 - 02/2014
5	COVID-19 05/2021 - 01/2020
5	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2016 - 08/2007
4	Infections 05/2021 - 07/2005
4	Critical Illness (Critically Ill) 11/2020 - 01/2016
4	Sepsis (Septicemia) 10/2020 - 01/2017
4	Splenomegaly 01/2016 - 02/2006
3	Inflammation (Inflammations) 01/2022 - 08/2013
3	Lymphoma (Lymphomas) 01/2022 - 01/2019
3	Glucocorticoid Receptor Deficiency 01/2022 - 07/2014
3	Thrombotic Microangiopathies 12/2021 - 12/2020
3	COVID-19 related pediatric multisystem inflammatory disease 05/2021 - 08/2020
3	Lymphopenia (Lymphocytopenia) 01/2021 - 10/2020
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 03/2014
3	Philadelphia Chromosome 01/2019 - 12/2017
3	Lymphadenopathy 01/2016 - 09/2006
2	Neutropenia 01/2022 - 12/2013
2	Thrombocytopenia (Thrombopenia) 01/2022 - 11/2020
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Vascular System Injuries 12/2021 - 04/2021
2	Fever (Fevers) 10/2021 - 02/2017
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020 - 02/2017
2	Multiple Myeloma 01/2018 - 09/2016
2	Hyperferritinemia 02/2017 - 06/2013
2	Mucositis 01/2017 - 11/2012
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2016 - 10/2012
2	Body Weight (Weight, Body) 10/2014 - 04/2013
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 12/2013 - 07/2005
1	Leukopenia 01/2022
1	Anemia 01/2022
1	Lymphadenitis (Adenitis) 01/2022
1	Histiocytic Necrotizing Lymphadenitis (Kikuchi Disease) 01/2022
1	Castleman Disease (Castleman's Disease) 01/2022

Drug/Important Bio-Agent (IBA)

19	Chimeric Antigen ReceptorsIBA 01/2022 - 04/2013
17	CytokinesIBA 01/2022 - 01/2008
11	Sirolimus (Rapamycin)FDA Link 01/2020 - 09/2006
8	Interleukin-6 (Interleukin 6)IBA 01/2022 - 02/2014
7	tocilizumab (atlizumab)FDA Link 01/2022 - 04/2013
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2015
7	tisagenlecleucelIBA 01/2022 - 04/2013
6	AntibodiesIBA 01/2021 - 01/2008
6	Phosphotransferases (Kinase)IBA 01/2020 - 08/2012
5	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2016
4	GlucocorticoidsIBA 01/2022 - 01/2020
4	Pharmaceutical PreparationsIBA 01/2018 - 07/2014
3	InterferonsIBA 01/2022 - 02/2014
3	ProteomeIBA 01/2022 - 04/2021
3	Immunoglobulin G (IgG)IBA 05/2021 - 01/2008
3	ruxolitinibIBA 01/2021 - 10/2012
3	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 09/2008
3	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 03/2010
3	TOR Serine-Threonine KinasesIBA 01/2014 - 06/2009
3	MTOR InhibitorsIBA 10/2012 - 09/2008
2	Bortezomib (Velcade)FDA Link 01/2022 - 09/2016
2	Proteasome InhibitorsIBA 01/2022 - 09/2016
2	EmapalumabIBA 01/2022 - 01/2021
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2021
2	siltuximabIBA 01/2022 - 01/2016
2	ChromatinIBA 06/2021 - 07/2014
2	Interleukin-8 (Interleukin 8)IBA 01/2021 - 01/2020
2	Imatinib Mesylate (Gleevec)FDA Link 01/2021 - 01/2018
2	Fibrinogen (Factor I)FDA Link 01/2021 - 01/2018
2	Complement System Proteins (Complement)IBA 12/2020 - 01/2020
2	Biological ProductsIBA 10/2020 - 09/2013
2	nelarabine (506U78)FDA Link 10/2020 - 01/2020
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2019 - 08/2012
2	MLN 8237IBA 01/2019 - 11/2012
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2018
2	Monoclonal AntibodiesIBA 01/2018 - 08/2007
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2017 - 01/2014
2	Alkaline PhosphataseIBA 01/2017 - 11/2012
2	InterleukinsIBA 03/2014 - 02/2014
2	Rituximab (Mabthera)FDA Link 08/2013 - 08/2007
1	CytosineIBA 11/2022
1	palbociclibIBA 01/2022
1	SEC Translocation ChannelsIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	tofacitinibIBA 01/2022
1	ribociclibIBA 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	Asparaginase (Elspar)FDA Link 01/2022
1	Interferon Type IIBA 01/2022
1	GlutaminaseIBA 01/2022
1	Glutamine (L-Glutamine)FDA Link 01/2022

Therapy/Procedure

38	Therapeutics 01/2022 - 02/2006
14	Drug Therapy (Chemotherapy) 01/2022 - 08/2007
9	Immunotherapy 01/2022 - 02/2014
2	Critical Care (Surgical Intensive Care) 11/2020 - 02/2017
2	Transplantation 01/2020 - 01/2018
2	Hematopoietic Stem Cell Transplantation 01/2019 - 11/2013